Syndax Pharmaceuticals SNDX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's additional paid-in capital?
- Syndax Pharmaceuticals (SNDX) reported additional paid-in capital of $1.59B in Q1 2026.
- How has Syndax Pharmaceuticals's additional paid-in capital changed year-over-year?
- Syndax Pharmaceuticals's additional paid-in capital increased by 4.6% year-over-year, from $1.52B to $1.59B.
- What is the long-term trend for Syndax Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's additional paid-in capital has grown at a 13.9% compound annual growth rate (CAGR), from $820.82M to $1.57B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.